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Abstract
Purpose—Previous research identified differences in breast cancer-specific mortality across four
"intrinsic" tumor subtypes: luminal A, luminal B, basal-like, and human epidermal growth factor
receptor 2 positive/estrogen receptor negative (HER2+/ER−).
Experimental Design—We used immunohistochemical markers to subtype 1149 invasive
breast cancer patients (518 African American, 631 white) in the Carolina Breast Cancer Study, a
population-based study of women diagnosed with breast cancer. Vital status was determined
through 2006 using the National Death Index, with median follow-up of 9 years.
Results—Cancer subtypes luminal A, luminal B, basal-like and HER2+/ER- were distributed as
64%, 11%, 11% and 5% for whites, and 48%, 8%, 22% and 7% for African Americans,
respectively. Breast cancer mortality was higher for patients with HER2+/ER- and basal-like
breast cancer compared to luminal A and B. African Americans had higher breast-cancer specific
mortality than whites, but the effect of race was statistically significant only among women with
luminal A breast cancer. However, when compared to the luminal A subtype within racial
categories, mortality for patients with basal-like breast cancer was higher among whites (HR=2.0,
95% CI: 1.2, 3.4) than African Americans (HR=1.5, 95% CI: 1.0, 2.4), with the strongest effect
seen in postmenopausal white women (HR=3.9, 95% CI: 1.5, 10.0).
Conclusions—Our results confirm the association of basal-like breast cancer with poor
prognosis, and suggest that basal-like breast cancer is not an inherently more aggressive disease in
African American women compared to whites. Additional analyses are needed in populations with
known treatment profiles to understand the role of tumor subtypes and race in breast cancer
mortality, and in particular our finding that among women with luminal A breast cancer, African
Americans have higher mortality than whites.
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Statement of Translational Relevance
Previous research identified differences in breast cancer-specific mortality across four
"intrinsic" tumor subtypes: luminal A, luminal B, basal-like, and human epidermal
growth factor receptor 2 positive/estrogen receptor negative (HER2+/ER−). Using data
from a population-based study, we observed that African American women had higher
breast cancer mortality than whites, but the effect of race was statistically significant only
for women with Luminal A breast cancer, a subtype with defined therapeutic targets.
Race-stratified estimates for the effect of “intrinsic” subtype on mortality indicated that
basal-like breast cancer was not inherently more aggressive in African American women.
For smaller tumors, patients with basal-like breast cancer showed greater lymph node
involvement than luminal A, while the reverse was true for larger tumors. Heterogeneity
was observed in the relationship between tumor subtypes and long-term survival, with
cross-over effects after 5 years of follow-up.
Introduction
Although breast cancer survival has increased substantially over the last 30 years, a large
racial disparity remains, with African Americans experiencing higher mortality and shorter
survival time than whites [1]. The difference is particularly pronounced among women
diagnosed prior to 50 years of age. Prognostic differences between breast tumor subtypes
could contribute to the survival disparity, as the subtypes are not equally distributed between
race and age groups [2,3]. Breast tumors may be classified using five immunohistochemical
(IHC) tumor markers: estrogen receptor (ER), progesterone receptor (PR), human epidermal
growth factor receptor-2 (HER2), human epidermal growth factor receptor-1 (HER1) and
cytokeratin 5/6 (CK 5/6) [2,4–8].
As demonstrated in a previous analysis of patients from the Carolina Breast Cancer Study
(CBCS), although luminal A (ER+ or PR+ and HER2−) is the most common IHC subtype
overall, pre-menopausal African American women have a high prevalence of basal-like
breast cancer (ER-, PR-, HER2- and either HER1+ or CK 5/6+) [2]. There are currently no
targeted therapies for the basal-like subtype, which has higher mortality than the most
common subtype, luminal A. Patients with luminal A tumors can be treated with estrogen
receptor inhibitors such as tamoxifen or aromatase inhibitors. Tumors expressing HER2 but
not ER or PR (HER2+/ER− subtype) were associated with the worst survival in the CBCS
[2], although the development of trastuzamab and other HER2-targeted agents to treat
HER2+ tumors has since improved prognosis. Carey et al [2] found that the HER2+/ER-
subtype was fairly rare in all age and race groups, comprising less than 10% of cancers in
each subpopulation.
Other studies have replicated the finding that basal-like breast cancer is more common in
young African Americans [3,9,10] and younger women in Africa [11,12] compared to
European American, European, and Asian women [3-8,13–21]. Additionally, nearly all
studies agree that basal-like and HER2+/ER- negative tumors have poorer prognoses than
luminal A, regardless of the source population [3,4,6,7,10,15–24]. However, many of these
studies used only three IHC markers (ER, PR, and HER2) to classify subtypes, thus
combining all basal-like and unclassified cancers into a single ‘triple negative’ subtype. As
several studies have corroborated that these two subtypes are biologically and prognostically
distinct [4,7,13,15,22–23], subtype misclassification could substantially bias effect
estimates.
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Despite the abundance of studies on this topic, only the original CBCS study [2], an Atlanta-
based case-control study [3], and a California-based cancer registry study [20] have
compared IHC subtype frequency distributions in multiracial, population-based samples. Of
those, only one study presented racial differences in survival by IHC subtype [3], albeit with
ER, PR and HER2 markers only, and none have examined survival differences by race and
menopausal status. For this reason, an updated analysis of the CBCS data, which includes an
additional 4 years of follow-up and nearly 1000 more patients enrolled during Phase II of the
study, was conducted to help elucidate the relationship between race, menopausal status,
breast cancer IHC subtype and survival. Recognizing that the effect of tumor markers may




The CBCS is a population-based, case-control study conducted in 24 counties of North
Carolina (NC). Invasive breast cancer patients diagnosed from 1993–1996 (Phase I) and
1996–2001 (Phase II) were identified using rapid case ascertainment in cooperation with the
NC Central Cancer Registry. Survival results were previously published for Phase I [2]. For
both phases of the CBCS, patients were selected using weighted sampling probabilities for
each race and age subgroup to ensure approximately equal numbers of pre- and post-
menopausal African Americans, and pre- and post- menopausal whites [27]. Overall, 1808
women with breast cancer were enrolled, 1149 of which had tumor tissue available for
subtype analysis. This included 238 pre-menopausal African Americans, 280
postmenopausal African Americans, 323 pre-menopausal whites and 308 postmenopausal
whites.
Race was determined by self-report, with all individuals categorized as either African
American or white. Less than 2% of participants self-identified as multiracial, Hispanic or
other race/ethnicities and were classified as white for statistical analyses. Information on
menopausal status and other potential covariates were collected during in-home interviews
[9]. Women younger than 50 years were considered postmenopausal if they had undergone
natural menopause, bilateral oophorectomy, or irradiation to the ovaries, while women older
than 50 years were assigned a menopausal status based on menstrual cessation [2]. Tumor
size, axillary lymph node status, and stage at diagnosis were abstracted from medical
records. ER and PR status were also abstracted from the medical record for approximately
80% of patients [2].
IHC Subtypes
The collected tumor tissue was sectioned and stained for a panel of immunohistochemical
(IHC) markers at the Immunohistochemistry Core Laboratory at the University of North
Carolina, Chapel Hill. Using medical records and markers modeling gene expression
profiles of HER2, HER1, CK 5/6, and, if necessary, ER and PR, IHC subtypes were
assigned as follows: luminal A (ER+ and/or PR+, HER2−), luminal B (ER+ and/or PR+,
HER2+), HER2+/ER− (ER−, PR−, HER2+), basal-like (ER−, PR−, HER2−, HER1+ and/or
CK 5/6+) or unclassified (negative for all 5 markers). A more detailed description of the
development of these IHC markers as proxies for gene expression analysis can be found
elsewhere [2,28,29].
Outcome Assessment
Participants were matched to National Death Index (NDI) recorded deaths occurring prior to
January 1, 2007. True matches were determined using weighted probabilistic scores and a
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priori matching cut-points to establish a maximum of one match per individual. The NDI
also provided date of death and cause of death for each expired individual. The sensitivity of
National Death Index search is estimated to 98% and specificity approximately 100% [30].
Using International Classification of Disease (ICD) codes, we categorized cause of death as
either breast cancer-specific (ICD-9 174.9 or ICD-10 50.9) or other cause of death based on
the first listed primary cause of death.
Statistical Analysis
We first performed descriptive analyses of age, menopausal status, stage, IHC subtype,
hormone receptor status, vital status and cause of death for each racial group. Frequency
distributions were adjusted for the sampling probabilities used to identify the appropriate
proportion of eligible patients in each race and age group (Phase I: 100% of African
Americans <50, 75% of African Americans ≥50, 67% of whites <50, and 20% of whites
≥50; Phase II: 100% of African Americans, 50% of whites <50, and 20% of whites ≥50).
After censoring living individuals at December 31, 2006, we modeled breast cancer-specific
and overall survival curves by race, menopausal status, IHC subtypes, and ER, PR, and
HER2 status using the Kaplan-Meier method. For the breast cancer-specific analysis, we
censored individuals who died of causes other than breast cancer at time of death. We
conducted additional analyses combining the luminal A and B subtypes and excluding
unclassified individuals. Survival curves were compared using a log-rank test, and log
cumulative hazards plots were examined for possible deviation from proportional hazards
assumptions.
We then conducted survival comparisons for race, menopausal status, IHC subtype, and
hormone receptor status using Cox proportional hazards models, regardless of whether
proportional hazards assumptions were met. We selected age, race, and date of diagnosis as
covariates with the aid of a directed acyclic graph [31,32], a technique that uses a priori
knowledge of the relationship between the main exposure, possible covariates, and survival
to determine the set of necessary adjustment variables. Hazard ratios (HRs) were adjusted
for age and race because of their known associations with both IHC subtype [2,9] and
survival. Date of diagnosis was included in the models as a continuous variable to adjust for
secular changes in breast cancer diagnosis, assessment, and treatment over the enrollment
period.
As there is evidence that IHC subtype can be assessed in precancerous in situ lesions [9],
stage at diagnosis could represent an intervening variable between IHC subtype and breast
cancer mortality. Therefore, adjusting for stage at diagnosis could potentially bias HR
estimates [33]. However, stage at diagnosis also serves as a proxy for treatment, and
analyses of breast cancer survival commonly adjust for stage. Thus, we present models
adjusted and not adjusted for stage at diagnosis in addition to age, race and date of
diagnosis. We excluded a number of potential confounding variables, such as socioeconomic
status (income, education), and body size (body mass index, waist hip ratio) because we
only had information on baseline measures, and we felt that adjusting for non-time varying
estimates would be insufficient and potentially biasing if they were affected by a woman’s
breast cancer diagnosis. No treatment information was available for participants in the
CBCS.
After conducting these survival analyses in the entire study population using both
adjustment sets (i.e. race, age, and date of diagnosis or race, age, date of diagnosis and stage
of disease), we then completed the same analyses within racial strata using both adjustment
sets (excluding race), and within strata defined by race and menopausal status, adjusting for
age and enrollment year only. We also estimated hazard ratios (HRs) for the effect of stage,
O’Brien et al. Page 4













tumor size, lymph node status or presence of metastatic disease on mortality within each
subtype strata to better evaluate the interaction between stage and IHC subtype. These
models were adjusted for race, age and date of diagnosis. Additionally, the relationship of
axillary lymph node status (percent of patients exhibiting lymph nodes positive for
malignancy, average number of positive nodes, and percent of positive nodes for each
patient) and tumor size (≤2 cm, 2–5 cm, > 5 cm) was examined using Chi-square and
Wilcoxon rank sum tests.
To assess departure from proportional hazards assumptions, we examined 1-, 2-, or 3-
degree polynomial time by exposure interaction terms. We also modeled the change in the
HR over time using restricted cubic splines [34], with knots at the 5th, 35th, 65th, and 95th
percentiles. We examined the polynomial and spline models for patterns in how the HRs
changed over time to identify meaningful cut-points for appropriate time-stratified
proportional hazards models. All analyses were conducted using SAS version 9.2 (SAS




Characteristics of study participants are presented in Supplementary Table 1. African
American patients were younger than white patients, more likely to be pre-menopausal (41%
versus 32%), diagnosed at later stage (65% versus 48% at Stage II or higher) and have ER-
negative (51% versus 32%) or PR-negative (55% versus 36%) disease. The proportion of
patients with HER2-positive disease was similar in African Americans and whites (15% and
18%, respectively). The distribution of "intrinsic" IHC subtypes according to race and
menopausal status indicated that although luminal A was the most common subtype of
breast cancer overall (57%, 67%, 40% and 55% of premenopausal white, postmenopausal
white, premenopausal African American and postmenopausal African American women,
respectively), premenopausal African American women exhibited a higher percentage of
basal-like tumors (29%) compared with premenopausal whites (15%), postmenopausal
whites (10%), and postmenopausal African Americans (17%).
Survival statistics
Median follow-up time was 9.0 years (range 0.2 to 13.7 years). There were 347 total deaths,
with 239 due to breast cancer. Time plots for a 5% random sample of participants can be
seen in the supplement (Supplementary Figures 1 and 2). We estimated the five-year risk of
death due to any cause as 17% and the five-year risk of death due to breast cancer as 14%
(Kaplan-Meier curve and table found in Supplementary Figure 3). African American women
were more likely to die of breast cancer than whites, with 17% 5-year breast cancer-specific
mortality, versus 11% for whites (Supplementary Table 2). Patients with luminal A tumors
had the lowest 5-year breast cancer-specific mortality (9%), followed by luminal B (12%).
Women with HER2+/ER- tumors exhibited the highest breast cancer-specific mortality, with
26% deaths within 5 years of diagnosis, followed by basal-like and unclassified, with 24%
and 18% deaths, respectively.
Survival statistics and HRs for breast cancer-specific mortality for all study participants
combined are presented in Supplementary Table 3. Statistically significant differences in
breast cancer-specific mortality were observed according to race, menopausal status, IHC
subtype, ER, PR, and HER2 status (P-value for log rank test less than 0.05). African
Americans had higher breast-cancer specific mortality than whites (HR= 1.7, 95% CI; 1.3,
2.2), even after adjustment for stage at diagnosis (HR= 1.7, 95% CI: 1.3, 2.2), or stage and
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IHC subtype (HR= 1.6, 95% CI: 1.2, 2.0). Analyzed as single markers, patients with HER2+
tumors did not have a worse prognosis than patients with ER-negative or PR-negative
tumors (HR= 1.5, 95% CI: 1.1, 2.0; HR = 1.6, 95% CI: 1.2, 2.1; and HR= 1.7, 95% CI: 1.3,
2.2 for the effect of HER2, ER, and PR, respectively), particularly after adjusting for stage at
diagnosis (HR= 1.2, 95% CI: 0.9, 1.7; HR = 1.4, 95% CI: 1.1, 1.8; and HR= 1.5, 95% CI:
1.1, 1.9). However, when these tumor markers were considered jointly and incorporated into
the five-marker scheme defining “intrinsic” IHC subtypes, a different pattern emerged.
Among all patients, women with HER2+/ER− disease had the highest risk of death (HR=
2.3, 95% CI: 1.5, 3.6), followed by basal-like (HR= 1.7, 95% CI: 1.2, 2.4). Survival statistics
and HRs were also estimated for overall (all-cause) mortality (data not shown). HRs were
more precise but slightly attenuated using overall (all-cause) mortality as the outcome (data
not shown).
Subtype and race
Race-stratified Kaplan-Meier plots and HRs for the effect of race (African American versus
white) for each IHC subtype are presented in Figure 1. Although African American patients
showed higher breast cancer-specific mortality than whites for each IHC subtype, the effect
of race was statistically significant only among women with Luminal A breast cancer.
Adjustment for stage at diagnosis did not substantially change the magnitude of the HRs,
with the exception of the HER2+/ER- subtype, which showed a stronger association with
race after adjustment for stage.
Race-stratified survival results are presented in Table 1. HRs for menopausal status, ER, PR,
and HER2 were fairly similar for African Americans and whites, as were most of the race-
stratified IHC subtype effect estimates. HRs for basal-like breast cancer compared to
Luminal A were slightly higher among whites than African Americans. Adjustment for stage
at diagnosis resulted in HRs of similar direction and magnitude for race and menopausal
status, but resulted in attenuated effect estimates for IHC subtype and hormone receptor
status. The most extreme example was among whites, where the HR for HER2+/ER-versus
luminal A breast cancer was 2.4 when adjusted for age, and date of diagnosis, but only 1.4
when adjusted for age, date of diagnosis, and stage.
Subtype, race and menopausal status
HRs stratified according to race and menopausal status are presented in Table 2. HRs were
imprecise owing to small sample size within strata. For the IHC subtype analysis, HRs were
highest among postmenopausal whites with either HER2+/ER− or basal-like breast cancer,
compared to luminal A. The HER2+/ER− subtype consistently had the highest HR for each
patient subgroup. Importantly, HRs for basal-like breast cancer were slightly higher among
premenopausal white compared to premenopausal African American patients, and higher
among postmenopausal white compared to postmenopausal African American patients. HRs
for PR− vs. PR+, and HER2+ vs. HER2− were highest for postmenopausal whites, while
the HR for ER− vs. ER+ was highest among postmenopausal African American patients.
When these models were additionally adjusted for stage at diagnosis, effect estimates were
similar but attenuated.
Flexible modeling techniques
Results from polynomial time-interaction models indicated that the proportional hazards
assumption was valid when comparing breast cancer-specific mortality by menopausal
status (P=0.8) or HER status (P=0.4), but the assumption was violated when comparing race,
ER status, PR status, IHC subtype, and combined IHC subtype (P≤0.01 for each test) (data
not shown). For ER status, PR status and IHC subtype, a one-degree polynomial time-
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interaction provided the best model fit, but race and combined subtype required cubic time-
interaction terms.
After determining the best fit model for each exposure, we plotted the data to investigate
how the HR changed over time for each analysis. For example, the best polynomial model
for the subtype analysis was a 1-degree time interaction model, so this appears as 4 diagonal
lines, one for each subtype comparison (versus luminal A). Spline models were also plotted
for each exposure. Plots showing the best-fitting polynomial and spline models for breast
cancer-specific mortality and subtype are presented in Supplementary Figure 4. Based on
these plots, we concluded that stratifying HR estimates into two time periods, 0–5 years and
greater than 5 years, would be an appropriate way to capture heterogeneity in the HRs over
time without sacrificing interpretability of the effect estimates. Five years of follow-up was
the point where most HRs approached the null or changed directions for both the polynomial
and spline models.
Time-stratified estimates for breast cancer-specific mortality are provided in Table 3. Single
estimates are provided for models that did not violate the proportional hazards assumptions
(menopausal status, HER2 status). Effect estimates for basal-like and unclassified breast
cancer were greater than 1 in the first 5 years and less than 1 after 5 years of follow-up. The
HR for HER2+/ER− was higher in the first five years but remained greater than 1, while the
HR for luminal B increased slightly with time. HRs for ER and PR were greater than 1
during the first 5 years, but dropped to 1.0 or less than 1.0 for the second time period. HRs
for African American race were greater than 1 and statistically significant for both time
periods. HRs adjusted for stage showed similar patterns but were closer to the null (data not
shown).
Subtypes and stage
HRs for stage at diagnosis, tumor size, number of positive axillary lymph nodes and
presence of metastatic disease, overall and stratified by IHC subtype, are presented in Table
4. For all subtypes, later stage at diagnosis, larger tumor size, increasing number of axillary
lymph nodes, and presence of metastatic disease resulted in higher mortality. Trends were
increasing and monotonic, but differed slightly between subtypes. For basal-like tumors, the
HRs for a tumor measuring 2–5 cm versus <2 cm was 1.5 (95% CI: 0.8–2.9), whereas for
luminal A, luminal B and HER2+/ER- the HRs were greater than 2.0. For larger tumors (>5
cm), basal-like and luminal B tumors exhibited lower HRs than luminal A and HER2+/ER−.
It should be noted that CIs were wide and overlapped across IHC subtypes.
Subtypes and lymph node status
To further explore the relationship between IHC subtypes, tumor size and variables related
to axillary lymph node status, additional analyses were conducted. As presented in Table 5,
a stronger association was observed for each lymph node variable and increasing tumor size
for luminal A, luminal B and HER2+/ER−, unclassified, but not basal-like tumors.
Additional analyses were conducted comparing the distribution of lymph node variables in
basal-like versus luminal A patients. For tumors ≤ 2 cm, patients with basal-like breast
cancer had a higher percentage of lymph node positive tumors (P = 0.04), more positive
lymph nodes per patient (P = 0.03), and a higher percentage of positive lymph nodes per
patient (P = 0.01) than women with luminal A breast cancer. However, in larger tumors, the
reverse was true. For tumors >2–5 cm, each of the lymph node variables was higher among
luminal A compared to basal-like patients (P = 0.02 for all 3 tests of association).
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The prognostic significance of "intrinsic" IHC breast cancer subtypes was determined using
data from the Carolina Breast Cancer Study, a population-based epidemiologic study of
African American and white women in North Carolina with a median follow-up time of 9
years. We evaluated how hazard ratios for IHC subtypes were modified by race, menopausal
status, and duration of follow-up, and also examined the contributions of tumor size, lymph
node status and presence of metastatic disease. HRs for race, IHC subtypes, ER, PR, HER2
status and stage at diagnosis were consistent with previously reported data from other recent
studies [3,4,6,7,10,13,15–26]. Patients with HER2+/ER− breast cancer had the worst
prognosis, followed by basal-like. The CBCS was conducted prior to the introduction of
trastuzumab and other HER2-targeted agents to treat HER2+ tumors.
Race-stratified analyses in the CBCS indicated that breast cancer mortality was higher for
African American women compared to white women, even after adjustment for stage at
diagnosis and "intrinsic" IHC subtype. However, the effect of race was statistically
significant only among women with Luminal A breast cancer. HRs for basal-like breast
cancer compared to luminal A were slightly higher in white patients compared to African
Americans, and this was true among pre- as well as postmenopausal women. Thus, basal-
like breast cancer does not appear to be an inherently more aggressive in African American
women compared to whites in the CBCS. Racial differences in breast cancer mortality are
likely to be driven by differences in treatment and access to care (as represented by income
or education) for Luminal A and other subtypes of breast cancer [35], in addition to the
higher prevalence of basal-like breast cancer among younger African American women.
Although CBCS results generally agree with those reported by Lund et al [3], our analyses
provide more precise estimates with additional information about the relative prognostic
importance of each IHC subtype within racial strata and we were able to provide separate
estimates for basal-like and unclassified tumors. Classical prognostic factors such as stage at
diagnosis, tumor size, number of affected lymph nodes and presence of metastases were
predictive of mortality across all IHC subtypes. As reported in previous studies [14,36], we
observed a somewhat attenuated relationship between tumor size and survival for basal-like
breast cancer, particularly when comparing HRs across IHC subtypes for tumors >2-5 cm in
size. For tumors of >2–5cm, only 41% of basal-like breast tumors exhibited positive axillary
lymph nodes, a lower percentage than for other IHC subtypes (range 47% to 61%). Lower
levels of lymph node metastasis could possibly contribute to the superior survival seen for
patients with larger basal-like breast tumors compared with patients diagnosed with
similarly sized tumors of other subtypes. Conversely, higher levels of lymph node metastasis
in smaller basal-like tumors could contribute to poor prognosis in this group of patients.
Since stage at diagnosis was predictive of mortality for each IHC subtype, and subtype was
predictive of mortality with and without adjustment for stage, we deduce that both IHC
subtype and stage affect prognosis and need to be evaluated together in the clinical setting.
One debatable issue is whether breast cancer-specific or all-cause mortality should be the
main outcome of interest. We chose to focus on breast cancer-specific mortality as the main
outcome, because we were interested in evaluating the effects of specific breast tumor-
related markers on survival time. However, since misclassification could have occurred if a
death was breast-cancer related, but not primarily due to breast cancer (e.g. heart disease
related to chemotherapy), or if the physician filling out the death certificate misattributed
cause of death (e.g. stating that death was due to lung cancer instead of breast cancer
metastasized to the lung), we conducted analyses using both outcomes. If most of the causes
of death were correctly attributed, we would expect to observe weaker but more precise
estimates for all-cause mortality than for breast cancer-specific mortality. Because this
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pattern was observed in our data, we conclude that valid inferences can be drawn based
upon breast cancer-specific mortality.
Statistical analyses using flexible modeling techniques for time-to-event data demonstrated
that HRs for IHC subtypes varied over time. Interestingly, for basal-like and unclassified
tumors, the time-stratified effect estimates were on the opposite sides of the null. This
suggests that individuals who were triple negative for ER, PR and HER2 (which includes
basal-like, claudin-low and unclassified tumors) had higher mortality initially, when
compared to patients with luminal A breast cancer, but lower mortality once they survived
the first 5 years. Similar findings were reported by Dent et al [36,37] and Tischowitz et al.
[38]. With respect to breast cancer recurrence, several studies have shown high risk of early
relapse among hormone receptor-negative and triple-negative breast cancer patients, and a
more constant rate of relapse for hormone-receptor positive disease [39]. Some of the cross-
over effect may be due to the fact that only surviving women in each stratum are included
when estimating effects for later time periods [40].
Over twenty years ago, Gore et al. [41] reported non-proportional hazards for breast in
relation to menopausal status, nodal status, tumor size and other clinical variables, and
recommended a step-wise analysis of breast cancer survival in 5-year increments. While the
5-year cut-point is somewhat arbitrary, statistical tests of proportional hazards assumptions
using CBCS data indicated deviations from a constant HR. We used graphs of the survival
functions, polynomial models and spline models to select 5 years of follow-up as the optimal
cut-point for time stratification. Choosing defined cut-points for time-stratification allows
for a much simpler interpretation of hazard functions than would be possible with a
polynomial or spline model, but still allows for heterogeneity in HRs over time [25,26,34].
Regardless of the exact stratification point, we feel strongly that time-to-event analyses
should carefully evaluate proportional hazards assumptions and be open to exploring more
flexible models, as such methods may reveal information about the nature of exposure-
outcome relationship that cannot be captured using standard techniques. The fact that HRs
for IHC subtypes vary over time could have important policy implications in terms of
monitoring breast cancer survivors.
Our study has several limitations. The differences we observe by subtype and race may be
due to unobserved treatment differences by race. In addition, there is the potential for
misclassification of one or more covariates. Since the IHC tumor markers are proxies for
gene expression profiling, there may have been some misclassification of intrinsic breast
cancer subtype. Further misclassification may have occurred if medical record reports of ER
and PR status or disease stage were inaccurate, although previous exploration of this issue
among CBCS patients revealed that IHC cut-offs for receptor positivity were reasonably
standardized across all included laboratories [42,43]. Although some causes of death may
have been misattributed, validation studies showed the NDI to be highly accurate [44,45],
indicating that misclassification should not have substantially biased our findings.
Although all participants had complete data for race, age, and date of diagnosis, several had
missing data for stage at diagnosis, and 659 otherwise eligible individuals were excluded
entirely because of missing IHC subtype information. Analyses comparing patients with and
without IHC subtype information showed that the two groups were very similar in terms of
age, menopausal status, ER and PR status, and vital status, but those with missing subtype
information were more likely to have HER2-negative disease, lower stage at diagnosis,
smaller tumors, fewer positive lymph nodes, and were less likely to have died from their
breast cancer. Because stage at diagnosis and HER status, in particular, have strong effects
on mortality, excluding these individuals may have biased our results. However, this bias is
likely towards the null since patients with HER2-negative and/or lower stage disease are
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more likely to have luminal A disease, thus removing patients with longer survival times
from the referent group for HR estimation. Thus, differences in survival between patients
with luminal A compared to the other IHC subtypes may be even greater than observed in
our study.
Limited follow-up information in the CBCS makes it impossible to examine racial
disparities in access to care and associated mortality differences or to perform analyses using
the shorter endpoint of breast cancer recurrence. Although this was by far the largest multi-
racial study of breast cancer IHC subtypes and survival time, the sample size was still not
large enough to produce precise effect estimates in subgroups defined by menopausal status
and race. Therefore, we believe that additional analyses are needed in other equally diverse
populations with known treatment profiles to more fully understand the role of intrinsic
subtypes and race in breast cancer mortality.
Our study had several strengths. The study population was a large, population-based sample,
with sampling probabilities used to obtain unique diversity by race and age at diagnosis. The
population-based design facilitated ascertainment of a full spectrum of disease stages, which
is often not available in clinical trial-based samples. Another strength was that each
participant was given an extensive home interview and asked to provide medical records and
tumor samples. This provided us with detailed information on relevant covariates and
allowed us to conduct IHC analyses to assess cancer subtypes. Finally, because participant
follow-up began just after diagnosis and continued for an extended period of time using a
reliable data resource, there was minimal loss to follow-up.
In conclusion, long-term survival analysis of CBCS patients confirms the association of
basal-like breast cancer with poor prognosis. While our data show a higher prevalence of
basal-like breast cancer in younger African American patients, basal-like breast cancer does
not appear to be an inherently more aggressive disease in African American women
compared to whites. Disparities in access to care, including established treatments for ER+
(luminal A) breast cancer, could also contribute to higher breast cancer mortality in African
American women. Additional analyses are needed in populations with known treatment
profiles and recurrence data to more fully understand the role of tumor subtypes and race in
breast cancer mortality. Flexible statistical models that address heterogeneity for 0–5 years
versus greater than 5 years of follow-up will be needed, as recently demonstrated for ER+
and ER- breast cancer patients in the National Surgical Adjuvant Breast and Bowel Project
[46]. We also found that patients with larger basal-like tumors have on average fewer
positive lymph nodes and a better prognosis relative to patients with other “intrinsic”
subtypes. The complex interplay of tumor size, lymph-node status and prognosis is an
important area of investigation [47], and it will be interesting to determine whether our
findings are replicated in other patient populations.
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Table 2
Hazard Ratios for Breast Cancer Specific Mortality, Stratified by Race and Menopausal Status and Adjusted
for Age at Diagnosis and Date of Diagnosis
White African American
Premenopausal (n=323) Postmenopausal (n=308) Premenopausal (n=238) Postmenopausal (n=280)
Subtype
 Luminal A 1.00 1.00 1.00 1.00
 Luminal B 1.2 (0.6, 2.5) 2.9 (1.0, 8.4) 1.2 (0.5, 2.9) 1.3 (0.5, 3.6)
 Basal-like 1.8 (1.0, 3.4) 3.9 (1.5, 10.0) 1.3 (0.8, 2.3) 1.9 (0.9, 3.8)
 HER2+/ER− 2.1 (0.9, 5.0) 4.3 (1.4, 13.6) 1.9 (0.9, 4.2) 3.1 (1.3, 7.2)
 Unclassified 1.4 (0.7, 3.0) 2.1 (0.6, 7.4) 1.0 (0.5, 2.0) 1.9 (0.8, 4.3)
Subtype combined
 Luminal A or B 1.00 1.00 1.00 1.00
 Basal-like 1.8 (1.0, 3.2) 3.0 (1.2, 7.4) 1.3 (0.8, 2.2) 1.8 (0.9, 3.6)
 HER2+/ER− 2.0 (0.9, 4.8) 3.4 (1.1, 10.3) 1.9 (0.9, 4.0) 3.0 (1.3, 6.9)
ER status
 ER+ 1.00 1.00 1.00 1.00
 ER− 1.4 (0.9, 2.2) 2.1 (1.0, 4.2) 1.3 (0.8, 2.2) 2.3 (1.3, 3.9)
PR status
 PR+ 1.00 1.00 1.00 1.00
 PR− 1.9 (1.2, 3.0) 2.1 (1.0, 4.2) 1.4 (0.9, 2.3) 1.9 (1.1, 3.4)
HER2 status
 HER2− 1.00 1.00 1.00 1.00
 HER2+ 1.2 (0.7, 2.1) 2.3 (1.1, 5.1) 1.4 (0.8, 2.5) 1.5 (0.8, 2.9)
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Table 3
Time-Stratified Hazard Ratios (HRs), Breast Cancer Specific Mortality Adjusted for Race, Age at Diagnosis,
and Date of Diagnosis
Breast Cancer Specific Time Stratified HR (95% CI)
Years 0–5 Years >5
Race
 White 1.00
 African American 1.6 (1.2, 2.3) 1.9 (1.2, 3.0)
Menopause
 Premenopausal 1.00
 Postmenopausal 0.8 (0.6, 1.1)*
Subtypes
 Luminal A 1.00
 Luminal B 1.3 (0.7, 2.5) 1.5 (0.8, 2.8)
 Basal 2.7 (1.8, 4.0) 0.6 (0.3, 1.3)
 HER2+/ER− 2.9 (1.7, 5.0) 1.6 (0.8, 3.5)
 Unclassified 1.9 (1.2, 3.2) 0.8 (0.3, 1.8)
Combined Subtypes
 Luminal A and B 1.00
 Basal 2.5 (1.7, 3.7) 0.6 (0.3, 1.1)
 HER2+/ER− 2.8 (1.6, 4.6) 1.5 (0.7, 3.2)
ER status
 ER+ 1.00
 ER− 2.5 (1.8, 3.5) 0.7 (0.4, 1.1)
PR status
 PR+ 1.00
 PR− 2.2 (1.6, 3.1) 1.0 (0.6, 1.6)
HER2 status
 HER2− 1.00
 HER2+ 1.4 (1.0, 1.8)*
*
single estimate given because proportional hazards assumption was not violated
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